ArticleCureus2025
Retrospective Electronic Medical Records Study to Understand the Usage Patterns and Patient Profiles of Those Prescribed Amlodipine and Its Combinations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a lifestyle disorder with a target blood pressure (BP) <140/90 mmHg. Amlodipine, a calcium channel blocker (CCB), is the first-line choice of treatment. This study aims to assess the effectiveness, tolerability, and treatment pattern of amlodipine or its combinations in patients with hypertension. METHODOLOGY: This retrospective, electronic medical records (EMR)-based longitudinal study analyzed anonymized data of hypertensive patients with prescriptions for amlodipine or its combinations. The primary aim was to understand the usage patterns, while the secondary goals were to assess effectiveness and tolerability. Outcome measures included changes in mean systolic BP (SBP) and diastolic BP (DBP), and the incidence of pedal edema.
resultsMost of the participants were aged 40 to 64 years (65.47%) and were predominantly male (52.85%). Dyslipidemia and diabetes mellitus (DM) were the most common comorbidities. There was a statistically significant reduction in SBP and DBP from visit 1 to visit 2 with amlodipine or its combination therapies (p < 0.001), irrespective of any comorbid condition. Pedal edema occurred in 0.91% of patients, notably lower than the reported 1.7%-32%.
conclusionAmlodipine or its combinations demonstrated a significant reduction in BP with a very low incidence of pedal edema. Hence, amlodipine shows good tolerability and effectiveness in the Indian population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.